Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Last trade$67.99
Day change+$0.885 (+1.32%)
Day range$65.42 – $68.32
Volume1,090,753
Market cap$16.37B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$16.37B
Price / earnings
18.5×
Price / book
8.93×
Price / sales
6.56×
EV / sales
6.44×
EV / EBITDA
15.57×
Profitability
Earnings per share
$3.63
Return on assets
35.22%
Return on equity
48.27%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.21×
Quick ratio
3.14×
Cash ratio
0.74×
Cash flow
Price / cash flow
13.96×
Price / free cash flow
14.1×
Free cash flow
$1.16B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EXEL, quarterly periods
Line item
Q3 FY2026 Oct 2, 2026
Q2 FY2026 Jul 3, 2026
Q1 FY2026 Apr 3, 2026
Q4 FY2025 Jan 2, 2026
Q3 FY2025 Oct 3, 2025
Q2 FY2025 Jul 4, 2025
Q1 FY2025 Apr 4, 2025
Q4 FY2024 Jan 3, 2025
Revenue
$658.7M
$628.69M
$610.81M
$598.66M
$597.76M
$568.26M
$555.45M
$566.76M
Cost of revenue
$26.23M
$20.66M
$19.95M
$26.48M
$18.57M
$19.47M
$19.17M
$19.97M
Gross profit
$632.46M
$608.03M
$590.86M
$572.18M
$579.18M
$548.79M
$536.28M
$546.79M
Selling, general and administrative
$154.56M
$147.63M
$139.6M
$123.02M
$123.66M
$134.86M
$137.18M
$134.33M
Research and development
$209.48M
$211.99M
$199.92M
$213.25M
$199.16M
$200.36M
$212.23M
$249M
Total operating expenses
$364.04M
$359.62M
$339.52M
$336.97M
$342.64M
$335.22M
$349.42M
$383.58M
Operating income
$268.42M
$248.41M
$251.34M
$235.22M
$236.54M
$213.58M
$186.86M
$163.21M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$282.79M
$262.68M
$267.69M
$252.69M
$252.41M
$230.42M
$205.69M
$184.77M
Income taxes
$64.69M
$50.63M
$57.22M
$8.16M
$58.84M
$45.57M
$46.07M
$44.91M
Net income
$218.1M
$212.05M
$210.47M
$244.53M
$193.58M
$184.85M
$159.62M
$139.86M
Net income attributable to common shareholders
$218.1M
$212.05M
$210.47M
$244.53M
$193.58M
$184.85M
$159.62M
$139.86M
EBITDA
$275.36M
$255.4M
$258.29M
$242.86M
$263.78M
$220.92M
$194.2M
$171.1M
Basic earnings per share
$0.88
$0.85
$0.81
$0.92
$0.72
$0.68
$0.57
$0.49
Diluted earnings per share
$0.85
$0.82
$0.79
$0.88
$0.69
$0.65
$0.55
$0.48
Recent news
Company coverage with links to the original publishers.
Exelixis faces a patent cliff for its blockbuster drug Cabometyx by 2030, but the company's future hinges on zanzalintinib, an experimental cancer drug expected to receive FDA approval by March 2027. The drug showed modest survival benefits in metastatic colorectal cancer trials and could generate $5 billion in sales by 2033 if approved across multiple indications. Despite regulatory delays and competitive pressures, Exelixis' shares appear reasonably valued at 16.3x forward earnings.
Exelixis, an oncology-focused biotechnology company, is highlighted as a stock to watch with a Zacks Rank #3 (Hold) and VGM Score of A. The company demonstrates strong growth potential with a Growth Style Score of A and forecasted year-over-year earnings growth of 22.4% for the current fiscal year. Five analysts have revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $3.77 per share.
The article recommends five biotech stocks as attractive long-term investments: Vertex Pharmaceuticals for its cystic fibrosis dominance and kidney disease pipeline; Amgen for its diversified portfolio with 17 products showing double-digit growth; Gilead Sciences for its strong HIV drug portfolio and expanding oncology presence; Exelixis for its successful oncology focus with Cabometyx; and Regeneron Pharmaceuticals for its recovery driven by new Eylea formulation and Dupixent growth.
Exelixis reported Q3 2026 adjusted EPS of 94 cents, beating consensus estimates by 5 cents, with revenue growth of 10.2% to $658.7 million. Cabometyx sales surged to $603.2 million, capturing 49% of the RCC oral TKI market. The company maintained 2026 revenue guidance of $2.50-$2.55 billion and repurchased $250 million in shares. Zanzalintinib regulatory decision was extended to March 2027, while the company advances multiple pipeline studies in colorectal cancer, renal cell carcinoma, and other oncology indications.
Exelixis reported Q3 2026 revenue of $658.7 million, up 10.2% year-over-year, beating the consensus estimate of $653.06 million by 0.86%. EPS came in at $0.94, exceeding the $0.89 estimate by 5.62%. Net product revenues, primarily driven by CABOMETYX, grew 11.4% to $604.92 million. However, the stock carries a Zacks Rank #4 (Sell) rating despite outperforming the S&P 500 by 12.6% over the past month.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.